Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Dillon

Showing results (1-10 of 176) with videos related to

Pageof 18
Sort By:
Hospital Medicine (London, England : 1998)|February 18, 2004
Cirrhotic ascites: a review of managementTharshanan Sivayokan, John F Dillon
The Practitioner|January 13, 2016
Early diagnosis improves outcomes in hepatitis CMichael H Miller, John F Dillon
Lancet (London, England)|August 23, 2025
Antisense oligonucleotide-directed liver therapy: a new tool in the MASH armamentarium?Paul N Brennan, John F Dillon
The International Journal on Drug Policy|June 30, 2015
The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literatureJosh T Coats, John F Dillon
Annals of Clinical Biochemistry|July 8, 2016
Gamma glutamyl transferase 'To be or not to be' a liver function test?John F Dillon, Michael H Miller
European Journal of Gastroenterology & Hepatology|July 12, 2008
Minocycline hepatitisThomas J Ford, John F Dillon
The International Journal on Drug Policy|June 26, 2017
DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacyAndrew Radley, Jan Tait, John F Dillon
Hepatology (Baltimore, Md.)|December 8, 2025
Addressing the utility of a novel score for "At-Risk" MASH in those with significant obesityJohn F Dillon, Damien Leith, Paul Brennan
Addiction (Abingdon, England)|August 22, 2022
Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic reviewSarah R Donaldson, Andrew Radley, John F Dillon
Substance Abuse Treatment, Prevention, and Policy|June 8, 2022
Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free worldSarah R Donaldson, Andrew Radley, John F Dillon
Pageof 18

Showing results (1-10 of 176) with videos related to

Sort By:
Pageof 18
Hospital Medicine (London, England : 1998)|February 18, 2004
Cirrhotic ascites: a review of managementTharshanan Sivayokan, John F Dillon
The Practitioner|January 13, 2016
Early diagnosis improves outcomes in hepatitis CMichael H Miller, John F Dillon
Lancet (London, England)|August 23, 2025
Antisense oligonucleotide-directed liver therapy: a new tool in the MASH armamentarium?Paul N Brennan, John F Dillon
The International Journal on Drug Policy|June 30, 2015
The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literatureJosh T Coats, John F Dillon
Annals of Clinical Biochemistry|July 8, 2016
Gamma glutamyl transferase 'To be or not to be' a liver function test?John F Dillon, Michael H Miller
European Journal of Gastroenterology & Hepatology|July 12, 2008
Minocycline hepatitisThomas J Ford, John F Dillon
The International Journal on Drug Policy|June 26, 2017
DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacyAndrew Radley, Jan Tait, John F Dillon
Hepatology (Baltimore, Md.)|December 8, 2025
Addressing the utility of a novel score for "At-Risk" MASH in those with significant obesityJohn F Dillon, Damien Leith, Paul Brennan
Addiction (Abingdon, England)|August 22, 2022
Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic reviewSarah R Donaldson, Andrew Radley, John F Dillon
Substance Abuse Treatment, Prevention, and Policy|June 8, 2022
Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free worldSarah R Donaldson, Andrew Radley, John F Dillon
Pageof 18